Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 12:06 PM
Ignite Modification Date:
2025-12-25 @ 11:58 AM
NCT ID:
NCT03030261
Group ID:
EG001
Title:
Continuation
Description:
* Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:
* 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+
* 2 mg pomalidomide daily on Days 1-21 of all cycles
* 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+
* Continuation therapy may continue until relapse or progression.
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
7
Serious Number At Risk:
18
Other Number Affected:
18
Other Number At Risk:
18
Study:
NCT03030261
Results Section:
NCT03030261
Adverse Events Module:
NCT03030261